Latest News
Cytokinetics Presents Data from the Phase 2 Clinical Trial of Reldesemtiv (CK-2127107) in Patients with SMA at the 2018 Annual SMA Conference
Today, Cytokinetics announced data from the Phase 2 clinical study of reldesemtiv in patients with SMA, presented in an oral presentation by John W. Day, M.D., Ph.D., Professor of Neurology […]
Read More ›Biogen to Present New Data at the 2018 Annual SMA Conference
Yesterday, Biogen announced it will present data from its SPINRAZA clinical development program –the largest of its kind, with more than six years of data–for spinal muscular atrophy (SMA) at […]
Read More ›The 2018 Annual SMA Conference is Here!
The 2018 Annual SMA Conference, now in its 30th year, is set to kick off on June 14 and continue into a weekend full of programs and events that bring […]
Read More ›Thank You to Our 2018 Annual SMA Conference Exhibitors!
Thank you to the following exhibitors who are generously supporting the 2018 Annual SMA Conference. This incredible and unique event would not be possible without your support! For more information […]
Read More ›Traveling with SMA
As the summer season nears, many families will make plans to travel across the country to exciting destinations or to spend time with those they love. This is no different […]
Read More ›Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015
Scholar Rock, a biotechnology company based in Boston, recently announced that it has completed dosing of the first cohort and is continuing enrollment of healthy volunteers in its Phase 1 […]
Read More ›